Related Experiment Video

Updated: May 11, 2026

Long-term Continuous EEG Monitoring in Small Rodent Models of Human Disease Using the Epoch Wireless Transmitter System
08:43

Long-term Continuous EEG Monitoring in Small Rodent Models of Human Disease Using the Epoch Wireless Transmitter System

Published on: July 21, 2015

Animal and human data: where are our concepts for drug-resistant epilepsy going?

Heidrun Potschka1

  • 1Institute of Pharmacology, Toxicology, and Pharmacy, Ludwig-Maximilians-University, Munich, Germany. potschka@pharmtox.vetmed.uni-muenchen.de

Epilepsia
|May 8, 2013
PubMed

Insights

Drug-resistant epilepsy poses a significant therapeutic challenge. Identifying the mechanisms of drug resistance is crucial for developing new treatments and personalized epilepsy management strategies.

Area of Science:

  • Neurology
  • Pharmacology
  • Epilepsy Research

Background:

  • Drug-resistant epilepsy affects a substantial number of patients, limiting treatment efficacy.
  • Current therapeutic strategies for epilepsy often fail in a significant patient cohort.
  • Understanding the basis of drug resistance is essential for advancing epilepsy care.

Purpose of the Study:

  • To highlight the challenge of drug-resistant epilepsy.
  • To emphasize the need for identifying factors contributing to drug resistance.
  • To advocate for collaborative research for novel therapeutic development.

Main Methods:

  • This study is a conceptual overview and synthesis of existing knowledge.
  • It calls for integrated experimental and clinical research efforts.
  • Focus is on elucidating mechanisms and validating new therapeutic concepts.

Main Results:

  • Drug resistance in epilepsy is a complex issue requiring multifaceted solutions.
  • Identifying specific resistance mechanisms is key to therapeutic advancement.
  • Collaboration is essential for translating research into clinical practice.

Conclusions:

  • Elucidating drug resistance mechanisms is paramount for developing effective epilepsy treatments.
  • Personalized treatment concepts and improved drug screening programs are potential outcomes.
  • Integrated research efforts are necessary to overcome therapeutic resistance in epilepsy.

More Related Videos

Pentylenetetrazole-Induced Kindling Mouse Model07:06

Pentylenetetrazole-Induced Kindling Mouse Model

Published on: June 12, 2018

Electrophoretic Delivery of γ-aminobutyric Acid (GABA) into Epileptic Focus Prevents Seizures in Mice07:01

Electrophoretic Delivery of γ-aminobutyric Acid (GABA) into Epileptic Focus Prevents Seizures in Mice

Published on: May 16, 2019

Related Concept Videos

Epilepsy and Seizures: Overview01:24

Epilepsy and Seizures: Overview

Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Antiepileptic Drugs: Glutamate Antagonists01:14

Antiepileptic Drugs: Glutamate Antagonists

Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...